Advertisement

Improved synergistic anticancer efficacy of quercetin in combination with PI-103, rottlerin, and G0 6983 against MCF-7 and RAW 264.7 cells

  • Akhilendra Kumar Maurya
  • Manjula Vinayak
Article
  • 50 Downloads

Abstract

Flavonoids have been chronicles of the history of a long way journey in the cure of physiological or pathophysiological conditions in various diseases including cancer. Our previous findings suggest the extensive mechanism of quercetin (QUE) mediated regression of cell survival, cell proliferation, oxidative stress, inflammation, and angiogenesis via modulating PI3K and PKC signaling in lymphoma as well as hepatocellular carcinoma. PI3K-PKC pathway is a key monitor of mammalian cells regulated by its different isoenzymes, which may exert similar or opposite cellular effects by differential coupling of signaling pathways. Put forward the invention of selective inhibitors against various isoenzymes is beneficial to reduce the burden of inclusive deleterious effects of drug for normal physiological process. Therefore, we hypothesized the improved anticancer efficacy of QUE in combination with isoenzyme inhibitors—rottlerin (ROT-PKCδ inhibitor), G0 6983 (PKCα inhibitor), and PI-103 (p110α-class I PI3K inhibitor) in MCF-7 and RAW 264.7 cells. QUE significantly improves the cytotoxicity of ROT + G0 6983 ranged 30–55% and PI-103 ranged 24–63% after 24–48 h against MCF-7 cells. Additionally in the presence of QUE, the improved cytotoxicity of ROT + G0 6983 is observed to range 69–75% and PI-103 ranged 45–88% after 24–48 h in RAW 264.7 cells. This increment in cell deaths are positively correlated with enhanced morphological alteration observed in MCF-7 cells. Further, QUE significantly increases the attenuation of PKCα level approximately by 50% in combination with PI-103. Overall results of the current study suggested that QUE improves the synergistic anticancer efficacy in combination with PI-103, ROT, and G0 6983 in MCF-7 and RAW 264.7 cells.

Keywords

Quercetin PI-103 Rottlerin G0 6983 PI3K PKC MCF-7 RAW 264.7 

Notes

Acknowledgements

MV is thankful to UGC-CAS program to Department of Zoology for infrastructural facilities.

Funding information

This research was supported by University Grants Commission (UGC), India (Project No. F 40-209/2011 (SR) dated June 29, 2011) and CSIR, India, for JRF & SRF (CSIR Award No. File No. 09/013(0338)/2010-EMR-I).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Allen-Petersen BL, Carter CJ, Ohm AM, Reyland ME (2014) Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer. Oncogene 33(10):1306–1315CrossRefGoogle Scholar
  2. Andres S, Pevny S, Ziegenhagen R, Bakhiya N, Schäfer B, Hirsch-Ernst KI, Lampen A (2017) Safety aspects of the use of quercetin as a dietary supplement. Mol Nutr Food Res 62.  https://doi.org/10.1002/mnfr.201700447
  3. Ashour AA, Abdel-Aziz AA, Mansour AM, Alpay SN, Huo L, Ozpolat B (2014) Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells. Apoptosis 19:241–258CrossRefGoogle Scholar
  4. Babu PR, Babu KN, Peter PL, Rajesh K, Babu PJ (2013) Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. Drug Dev Ind Pharm 39(6):873–879CrossRefGoogle Scholar
  5. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297–315CrossRefGoogle Scholar
  6. Berridge MV, Herst PM, Tan AS (2005) Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11:127–152CrossRefGoogle Scholar
  7. Brito AF, Ribeiro M, Abrantes AM, Pires AS, Teixo RJ, Tralhão JG, Botelho MF (2015) Quercetin in cancer treatment, alone or in combination with conventional therapeutics? Curr Med Chem 22(26):3025–3039CrossRefGoogle Scholar
  8. Castillo-Pichardo L, Dharmawardhane SF (2012) Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer. Nutr Cancer 64:1058–1069CrossRefGoogle Scholar
  9. Chan ST, Yang NC, Huang CS, Liao JW, Yeh SL (2013) Quercetin enhances the antitumor activity of trichostatin a through upregulation of p53 protein expression in vitro and in vivo. PLoS One 8:e54255CrossRefGoogle Scholar
  10. Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH, Li Y (2014) PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis 5:e1437CrossRefGoogle Scholar
  11. Chen X, Lv Q, Ma J, Liu Y (2018) PLCγ2 promotes apoptosis while inhibits proliferation in rat hepatocytes through PKCD/JNK MAPK and PKCD/p38 MAPK signalling. Cell Prolif 51(3):e12437CrossRefGoogle Scholar
  12. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440–446CrossRefGoogle Scholar
  13. Cote B, Carlson LJ, Rao DA, Alani AW (2015) Combinatorial resveratrol and quercetin polymeric micelles mitigate doxorubicin induced cardiotoxicity in vitro and in vivo. J Control Release 213:128–133CrossRefGoogle Scholar
  14. De Angelis C (2008) Side effects related to systemic cancer treatment: are we changing the promethean experience with molecularly targeted therapies? Curr Oncol 15:198–199CrossRefGoogle Scholar
  15. Del Follo-Martinez A, Banerjee N, Li X, Safe S et al (2013) Resveratrol and quercetin in combination have anticancer activity in colon cancer cells and repress oncogenic microRNA-27a. Nutr Cancer 65:494–504CrossRefGoogle Scholar
  16. Djuzenova CS, Fiedler V, Katzer A, Michel K, Deckert S, Zimmermann H, Sukhorukov VL, Flentje M (2016) Dual PI3K and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule. Oncotarget 7(25):38191–38209CrossRefGoogle Scholar
  17. Enzenmüller S, Gonzalez P, Debatin KM, Fulda S (2013) Chloroquine overcomes resistance of lung carcinoma cells to the dual PI3K/mTOR inhibitor PI103 by lysosome-mediated apoptosis. Anti-Cancer Drugs 24(1):14–19CrossRefGoogle Scholar
  18. Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Rincke G, Marks F (1994) Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 199:93–98CrossRefGoogle Scholar
  19. Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Okada M, Ohta M, Tsukamoto S, Parker P, Workman P, Waterfield M (2006) Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 14:6847–6858CrossRefGoogle Scholar
  20. Hong KK, Ball GE, Black DS, Kumar N (2015) The mosaic of Rottlerin. J Org Chem 80:10668–10674CrossRefGoogle Scholar
  21. Hou Y, Feng S, Wang L, Zhao Z, Su J, Yin X, Zheng N, Zhou X, Xia J, Wang Z (2017) Inhibition of Notch-1 pathway is involved in rottlerin-induced tumor suppressive function in nasopharyngeal carcinoma cells. Oncotarget 8(37):62120–62130CrossRefGoogle Scholar
  22. Jakubowicz-Gil J, Langner E, Bądziul D, Wertel I, Rzeski W (2014) Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. Neurotox Res 26(1):64–77CrossRefGoogle Scholar
  23. Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA (2015) Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer. BMC Cancer 15:89CrossRefGoogle Scholar
  24. Juneja M, Kobelt D, Walther W, Voss C, Smith J, Specker E, Neuenschwander M, Gohlke BO, Dahlmann M, Radetzki S, Preissner R, von Kries JP, Schlag PM, Stein U (2017) Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1. PLoS Biol 15(6):e2000784.  https://doi.org/10.1371/journal.pbio.2000784 CrossRefGoogle Scholar
  25. Kavithaa K, Sumathi S, Paulpandi M, Padma PR (2014) Increased anticancer efficacy by the combined administration of quercetin in multidrug resistant breast cancer cells. BMR Cancer Res 1:1–13Google Scholar
  26. Li J, Zhu F, Lubet RA, De Luca A, Grubbs C, Ericson ME, D’Alessio A, Normanno N, Dong Z, Bode AM (2013) Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G(2)/M arrest and apoptosis. Mol Carcinog 52(2):134–143CrossRefGoogle Scholar
  27. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627–644CrossRefGoogle Scholar
  28. Lu W, Lin C, Li Y (2014) Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/β-catenin and mTORC1 signaling in prostate and breast cancer cells. Cell Signal 26:1303–1309CrossRefGoogle Scholar
  29. Maurya AK, Vinayak M (2015a) Quercetin regresses Dalton’s lymphoma growth via suppression of PI3K/AKT signaling leading to upregulation of p53 and decrease in energy metabolism. Nutr Cancer 67(2):354–363CrossRefGoogle Scholar
  30. Maurya AK, Vinayak M (2015b) Modulation of PKC signaling and induction of apoptosis through suppression of reactive oxygen species and tumor necrosis factor receptor 1 (TNFR1): key role of quercetin in cancer prevention. Tumour Biol 36(11):8913–8924CrossRefGoogle Scholar
  31. Maurya AK, Vinayak M (2015c) Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line. Mol Biol Rep 42(9):1419–1429CrossRefGoogle Scholar
  32. Maurya AK, Vinayak M (2015d) Abstract A07: decline in the growth of murine T-cell lymphoma via modulation of PI3K signaling pathway: key role of quercetin and PI-103. Mol Cancer Ther 14:A07.  https://doi.org/10.1158/1538-8514.PI3K14-A07 CrossRefGoogle Scholar
  33. Maurya AK, Vinayak M (2016a) PI-103 and quercetin attenuate PI3K-AKT signaling pathway in T-cell lymphoma exposed to hydrogen peroxide. PLoS One 11(8):e0160686.  https://doi.org/10.1371/journal.pone.0160686 CrossRefGoogle Scholar
  34. Maurya AK, Vinayak M (2016b) Breast cancer stem cell mediated aberrant signaling and epithelial-mesenchymal transition targets: hope for breast cancer therapy. Int J Cancer Oncol 3(3):1–7Google Scholar
  35. Maurya AK, Vinayak M (2017a) Quercetin attenuates cell survival, inflammation and angiogenesis via modulation of AKT signaling in murine T-cell lymphoma. Nutr Cancer 69(3):470–480CrossRefGoogle Scholar
  36. Maurya AK, Vinayak M (2017b) PI-103 attenuates PI3K-AKT signaling and induces apoptosis in murine T-cell lymphoma. Leuk Lymphoma 58(5):1153–1161CrossRefGoogle Scholar
  37. No M, Choi EJ, Kim IA (2009) Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance. Cancer Biol Ther 8:2351–2361CrossRefGoogle Scholar
  38. Ohno I, Eibl G, Odinokova I, Edderkaoui M, Damoiseaux RD, Yazbec M, Abrol R, Goddard WA 3rd, Yokosuka O, Pandol SJ, Gukovskaya AS (2010) Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family. Am J Physiol Gastrointest Liver Physiol 298:63–73CrossRefGoogle Scholar
  39. Pandey SK, Patel DK, Maurya AK, Thakur R, Mishra DP, Vinayak M, Haldar C, Maiti P (2016) Controlled release of drug and better bioavailability using poly (lactic-co-glycolic acid) nanoparticles. Int J Biol Macromol 89:99–110CrossRefGoogle Scholar
  40. Pingili RB, Pawar AK, Challa SR (2015) Systemic exposure of paracetamol (acetaminophen) was enhanced by quercetin and chrysin co-administration in Wistar rats and in vitro model: risk of liver toxicity. Drug Dev Ind Pharm 41(11):1793–1800CrossRefGoogle Scholar
  41. Prevo R, Deutsch E, Sampson O, Diplexcito J, Cengel K, Harper J, O’Neill P, McKenna WG, Patel S, Bernhard EJ (2008) Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 68:5915–5923CrossRefGoogle Scholar
  42. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bjerke LM, Kelland L, Valenti M et al (2007) Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67:5840–5850CrossRefGoogle Scholar
  43. Schlachterman A, Valle F, Wall KM, Azios NG, Castillo L, Morell L, Washington AV, Cubano LA, Dharmawardhane SF (2008) Combined resveratrol, quercetin, and catechin treatment reduces breast tumor growth in a nude mouse model. Transl Oncol 1:19–27CrossRefGoogle Scholar
  44. Serrero M, Planès R, Bahraoui E (2017) PKC-δ isoform plays a crucial role in tat-TLR4 signalling pathway to activate NF-κB and CXCL8 production. Sci Rep 7(1):2384CrossRefGoogle Scholar
  45. Singh BN, Kumar D, Shankar S, Srivastava RK (2012) Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells. Biochem Pharmacol 84:1154–1163CrossRefGoogle Scholar
  46. Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stuckrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, Politi KA, Perera S, Getlik M, Heukamp LC, Ansen S, Zander T, Beroukhim R, Kashkar H, Shokat KM, Sellers WR, Rauh D, Orr C, Hoeflich KP, Friedman L, Wong KK, Pao W, Thomas RK (2009) Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A 106:18351–18356CrossRefGoogle Scholar
  47. Tuorkey MJ (2015) Cancer therapy with phytochemicals: present and future perspectives. Biomed Environ Sci 28:808e819CrossRefGoogle Scholar
  48. Wang Z, Shen GH, Xie JM, Li B, Gao QG (2018) Rottlerin upregulates DDX3 expression in hepatocellular carcinoma. Biochem Biophys Res Commun 495(1):1503–1509CrossRefGoogle Scholar
  49. Xu H, Zhao B, She Y, Song X (2018) Dexmedetomidine ameliorates lidocaine-induced spinal neurotoxicity via inhibiting glutamate release and the PKC pathway. Neurotoxicology 69:77–83CrossRefGoogle Scholar
  50. Yadav MK, Maurya AK, Rajput G, Manar KK, Vinayak M, Drew MGB, Singh N (2017a) New planar trans-copper (II) β-dithioester chelate complexes: synthesis, characterization, anticancer activity and DNA-binding/cleavage studies. J Coord Chem 70(4):1–20CrossRefGoogle Scholar
  51. Yadav MK, Maurya AK, Rajput G, Manar KK, Vinayak M, Drew MGB, Singh N (2017b) Synthesis, characterization, DNA binding and cleavage activity of homoleptic zinc (II) β-oxodithioester chelate complexes. J Coord Chem 70(18):3171–3185CrossRefGoogle Scholar
  52. Yin S, Sethi S, Reddy KB (2010) Protein kinase Cδ and caspase-3 modulate TRAIL-induced apoptosis in breast tumor cells. J Cell Biochem 111(4):979–987CrossRefGoogle Scholar
  53. Zamin LL, Filippi-Chiela EC, Dillenburg-Pilla P, Horn F, Salbego C, Lenz G (2009) Resveratrol and quercetin cooperate to induce senescence-like growth arrest in C6 rat glioma cells. Cancer Sci 100:1655–1662CrossRefGoogle Scholar
  54. Zhao J, Zhao J, Jiao H (2014) Synergistic growth-suppressive effects of quercetin and cisplatin on HepG2 human hepatocellular carcinoma cells. Appl Biochem Biotechnol 172:784–791CrossRefGoogle Scholar
  55. Zhu Y, Wang M, Zhao X, Zhang L, Wu Y, Wang B (2017) Hu W. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma. Oncotarget 8(14):22825–22834Google Scholar

Copyright information

© The Society for In Vitro Biology 2018

Authors and Affiliations

  1. 1.Biochemistry & Molecular Biology Laboratory, Centre for Advanced Study in Zoology, Institute of ScienceBanaras Hindu UniversityVaranasiIndia
  2. 2.Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical SciencesUniversity of Colorado Anschutz Medical CampusAuroraUSA

Personalised recommendations